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Abstract 
Recurrent respiratory papillomatosis (RRP), which is caused exclusively by human 
papilloma virus (HPV), is a rare condition characterized by recurrent growth of benign 
papillomata in the respiratory tract. The papillomata can occur anywhere in the 
aerodigestive tract but most frequently in the larynx, affecting both children and adults. 
The management of this entity remains still challenging since no specific definitive 
treatment exists. Nevertheless, novel surgical interventions as well as several adjuvant 
therapies have shown promising results in the long-term palliative management of this 
debilitating disease. Despite its mostly benign nature, RRP may cause significant 
morbidity and mortality because of its unpredictable clinical course and especially its 
tendency, albeit infrequent, for malignant transformation. In this article, we present two 
patients with RRP; one underwent bronchoscopic laser ablation in combination with 
inhaled interferon-alpha administration that led to a long-term regression of the disease 
while the other patient was diagnosed with transformation to squamous cell lung 
carcinoma with fatal outcome. We include a review of the current literature with special 
emphasis on RRP management and the potential role of HPV in the development of lung 
cancer. 
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Introduction 
Recurrent respiratory papillomatosis (RRP) is a rare disease in which multiple 
exophytic squamous wart-like lesions occur within the respiratory tract [1]. Although 
generally considered to be a pediatric disease, RRP frequently manifests itself in 
adulthood [2]. Human papilloma virus (HPV) is the causative agent of RRP. Out of more 
than 120 subtypes, viral subtypes 6 and 11 account for more than 90% of all RRP cases. 
HPV subtypes 16 and 18 have also been detected in papillomas, but are much less 
common [3]. 
The disease primarily involves the larynx, especially the vocal cords but also various 
extralaryngeal sites. The most frequent are, in decreasing order, oral cavity, trachea, 
bronchi, lung parenchyma and esophagus [4]. Despite its benign nature, RRP can bear 
considerable morbidity and mortality as lesions have a tendency to grow and extend 
throughout the entire respiratory tract causing severe airway obstruction, and they are 
also liable to recurrence after surgical resection. Additionally, in the rare case of 
malignant transformation, morbidity and mortality are increasing [5, 6]. The course of 
RRP varies; spontaneous remission is occasionally noted or the disease may maintain a 
stable state requiring only intermittent surgical procedures. In the majority of RRP cases, 
however, the disease takes a more aggressive course necessitating surgical treatment every 
few days to weeks and consideration of adjuvant medical therapy. The disease is a 
challenge for the treating physician, inflicts emotional encumbrance onto patients and 
families as well as causes great expenses to the healthcare systems [7, 8]. 
No specific treatment has hitherto been shown to be efficacious in eradicating RRP. 
However, progress has recently been made in the management, i.e. the development of 
new promising drugs. In this report, we describe two patients with RRP, one with 
successful long-term treatment, the other with lethal outcome, and review the recent 
knowledge about treatment and the potential link between HPV infection and lung 
cancer. 
Case Reports 
Case 1 
The patient’s history (a 41-year-old male, heavy smoker) dates back to December 1993, when he 
sought medical assistance because of progressive hoarseness, stridor and shortness of breath. He 
reported the onset of hoarseness in his early childhood without further examination or treatment. In 
addition, he mentioned atopy to several allergens, such as grass, pollen, pigeon feathers and wool. He 
was diagnosed with asthma and received medication with no substantial remission of the symptoms. 
In November 1994, he was admitted to our department presenting with worsening hoarseness, 
dyspnea on exertion, stridor and cough with blood-streaked sputum. Chest examination revealed 
diffuse in- and expiratory wheezing. Otherwise the physical examination was unremarkable. Laboratory 
tests showed a slight increase of total IgE. Arterial blood gases were normal. Spirometry showed 
decreased FEV1, FVC, FEV1%, FEF 25–75% and FIV1 (63, 71, 75, 52 and 70% of predicted values); 
compatible with intra- and extrathoracic obstruction. Computed tomography showed multiple polypoid 
formations throughout the larynx and in the upper third and mid-trachea. No lesions were noted in the 
lung parenchyma. 
Indirect laryngoscopy showed laryngeal papillomas on the vocal cords interfering with vocal cord 
closure during phonation. Fiberoptic bronchoscopy revealed multiple polypoid papillomas in the upper  
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two thirds of the trachea resulting in significant obstruction (fig. 1a). Biopsy confirmed the diagnosis of 
laryngotracheal papillomatosis. Molecular testing using polymerase chain reaction (PCR) identified 
HPV types 6 and 11 in papilloma tissue. 
Surgical removal of the papillomata was performed by carbon dioxide (CO2) and neodymium-
yttrium aluminum garnet (Nd:YAG) laser for the laryngeal and tracheal papillomata, respectively. The 
patient achieved partial response. But the rate of papilloma recurrence accelerated, necessitating 
monthly bronchoscopic laser vaporization of the lesions. From March 1995, adjuvant medical treatment 
was started in an attempt to control papilloma regrowth by daily inhalation of nebulized interferon-
alpha (3 MU/m
2 of body surface) in combination with isotretinoin (40 mg p.o. per day for two months, 
then escalated to 80 mg/day). In addition, intralesional injection of interferon-alpha (2.5 MU/m
2 of 
body surface) at the anterior commissure was performed. Four months later, isotretinoin was 
discontinued because of side effects. Inhaled interferon-alpha was continued for 28 months. 
This regimen led to increased intervals for resection and finally complete disappearance of the 
tracheal papillomas and substantial regression of the laryngeal lesions. At present, 13 years after the 
cessation of adjuvant therapy, the disease still remains in remission without regrowth of papillomas in 
the trachea and only a small residual papilloma at the anterior commissure (fig. 1b, c). Spirometry 
parameters are normalized (FEV1: 86%, FVC: 85%, FEF25–75%: 80%, FIV1: 96% of predicted values). 
The patient’s voice has also been improved and laser treatment is only done at a yearly routine visit 
compared to one every month before combined therapy. 
Case 2 
A 27-year-old female was admitted in March 1989 with a mass in the right upper lobe and an ill-
defined opacity in the left upper lobe associated with mediastinal widening (fig. 2a, b). Since infancy, 
she suffered from persistent hoarseness and she was diagnosed with laryngeal papillomatosis at nine 
months of age. She had undergone annual surgical excisions of the papillomas. There was no 
information regarding maternal genital HPV infection. Already two years prior to referral, chest X-ray 
had shown a lesion in the right upper lobe. A clinical diagnosis of pneumonia had been made and the 
patient had received several courses of antibiotics but the lesion was growing. Fiberoptic bronchoscopy 
revealed typical papillomas in the larynx and trachea and an exophytic mass obstructing the right upper 
lobe (fig. 2c, d). Biopsies from laryngotracheal lesions confirmed papillomatosis, whereas the occluding 
mass was a well-differentiated squamous cell carcinoma. HPV serotypes 6 and 11 were detected in 
biopsies from the papillomata by virological examination. The patient received radiotherapy with no 
response. Then, she underwent radical right upper lobectomy with mediastinal lymph node dissection 
as well as resection of the contralateral tumor. Dot blot hybridization with radioactive marked 
oligonucleotide probes on postoperative specimens showed infection with HPV 11 exclusively in 
carcinoma tissue, metastasis, papillomas and metaplastic tissue by PCR. However, all specimens from 
normal bronchial mucosa and normal lung tissue were negative [9]. Shortly after surgery the patient 
died from septic shock.  
Discussion 
RRP is a rare condition characterized by the presence of benign papillomatous (wart-
like) growths within the respiratory tract [1]. Its incidence is estimated at 2 per 100,000 in 
adults and 4 per 100,000 in children [1, 10]. The disease presents in 2 forms according to 
the age at onset. Juvenile RRP occurs in patients under 5 years, with 25% of the cases 
presenting during infancy [11]. The first presentation in adults is usually in the third and 
fourth decade of life. The juvenile form is considered to be more aggressive than the adult 
type, although severe cases of RRP can occur in adults [1, 12]. We assume that an 
infection with more aggressive HPV strains results in faster proliferation of papillomas 
and an earlier onset of symptoms.   
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It is well-documented that HPV is the causative agent of RRP [3]. Vertical 
transmission of the virus during gestation or during delivery is considered to be the major 
route of contracting the disease in children. The risk is thought to be higher in women 
with overt anogenital warts or disease from a recent HPV infection at the time of delivery 
[13]. The majority of patients with juvenile papillomatosis are vaginally delivered, first-
born children of HPV-infected teenage mothers compared to controls, representing a 
clinical triad that has been determined as a predisposing risk factor for RRP [14]. In 
adults, the infection is generally agreed to represent either a reactivation of a slowly 
progressing latent HPV infection or a newly acquired sexually transmitted disease 
following oral-genital contact. 
According to DNA studies, 130 different HPV types have been identified, classified 
into low- and high-risk types in their potential for malignant degeneration. Low-risk 
types 6 and 11 are almost universally involved in RRP. The same types are strongly 
associated with genital warts. HPV high-risk types 16, 18, 31 and 33 have rarely been 
described in RRP [3, 15]. Patients infected by type 11 develop more aggressive disease 
(e.g. significant airway obstruction), requiring frequent surgical procedures and adjuvant 
medical therapies, sometimes even tracheotomy to keep the airway patent [16]. HPV has 
a predilection for the stratified epithelium of either the cutaneous or mucosal surface. 
RRP is induced by HPV stem cell infection (principally keratinocyte) within the basal 
layer of airway mucosa [17]. HPV can activate the epidermal growth factor receptor 
(EGFR) pathway and inactivate several tumor-suppressor proteins, thus leading to 
cellular proliferation and defective epithelial differentiation [18]. These mechanisms 
eventually result in ‘cauliflower-like’ exophytic growths, the typical RRP lesions. They 
occur most commonly in anatomical areas where squamous epithelium is adjacent to 
ciliated columnar epithelium. Therefore, the major anatomic sites for RRP are the 
vestibule of the nose, the nasopharyngeal surface of the soft palate, the midline of the 
laryngeal surface of the epiglottis, the upper and lower margins of the laryngeal ventricle, 
the lower surface of the vocal folds, the carina and upper trachea (especially at 
tracheostomy sites). In addition, distal tracheal spread extending into the bronchi and 
pulmonary parenchyma has been observed [4]. 
Patients with RRP usually present with symptoms of airway involvement. Progressive 
hoarseness, stridor, dyspnea or acute respiratory distress and chronic cough are most 
frequent. However, the disease is easily misdiagnosed as asthma (as in our first patient), 
croup, chronic bronchitis and vocal nodules further delaying its definitive diagnosis and 
treatment [1, 11, 19]. The average time from onset of the symptoms to diagnosis ranges 
from 1 to 8 years [2]. 
Although basically benign, RRP causes significant morbidity and occasional mortality 
due to recurrence and spread throughout the respiratory tract, requiring frequent 
operations in cases of severe exacerbation. The natural history of RRP is quite variable 
including spontaneous regression, persistence and dissemination of lesions causing 
airway compromise and in rare instances progression to carcinoma. This unpredictable 
course is a challenge for the clinician. 
Therapeutic goals in the treatment of RRP include papilloma reduction, restoration of 
airway patency, amelioration of symptoms, prevention of disease spread and decrease in 
hospitalization for interventions [5, 17]. Although currently there is still no definite 
curative treatment in eradicating RRP, surgery remains the mainstay of treatment. The  
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aim is to remove papillomatous lesions as radically as possible to maintain a safe airway 
and functional phonation without damaging normal structures that would lead to 
complications such as dysphonia, excessive airway scarring and stenosis. Various 
techniques and instruments have been used to minimize the complications of surgery, 
including endoscopic debulking with microdebriders, excision with phonomicrosurgical 
instruments and laser ablation. The preferred methods are resection using CO2, Nd:YAG 
laser, pulse-dye laser and endoscopic microdebrider. Surgical treatment is relatively safe 
and effective for the management of RRP [20]. Despite successful removal, recurrence 
after surgery is common. Persistence of HPV genome within the tissue adjacent to lesions 
has been proposed as the main cause [21]. However, in our second case with cancer 
transformation, no HPV was found in adjacent normal mucosa, suggesting why in the 
first case radical local resection resulted in complete remission. 
Roughly, 20% of patients with RRP require adjunctive medical treatment in addition to 
surgery to control the disease. The current criteria for adjuvant therapy are the necessity 
for more than 4 surgical procedures annually, rapid regrowth of papillomata with airway 
compromise and/or remote multisite spread of the disease [11, 17]. The majority of 
treatments focus on immunomodulation, disruption of molecular signaling cascades or 
HPV replication resulting in apoptosis, inhibition of proliferation, growth arrest and/or 
promotion of normal differentiation in HPV-infected cells. The list includes antiviral 
agents (acyclovir, ribavirin, cidofovir), interferon, retinoids (oral metabolites or analogues 
of vitamin A), photodynamic therapy, zinc, anti-reflux medications, cyclooxygenase-2 
inhibitors, therapeutic/preventive vaccines (mumps vaccine, quadrivalent HPV vaccine, 
heat shock protein E7) and gene therapy (EGFR tyrosine kinase inhibitors) [22]. 
However, most therapies have been described only in small series or as anecdotal case 
reports showing some benefit but have not adequately been evaluated in powered 
randomized controlled trials to provide sufficient evidence for their consideration in RRP 
treatment. 
The most extensively investigated adjuvant therapy is interferon-alpha. Several studies 
have demonstrated its positive influence on outcome of patients. Leventhal and 
coworkers [23] showed that continuous application of interferon-alpha (median duration 
18 months) achieved a good response in 47 of 60 patients with RRP (22 complete and 25 
partial remissions). They suggest a 6-month trial of interferon-alpha initially. If there is 
no response after 6 months, treatment should be discontinued. With partial response and 
tolerable toxicity, continued treatment is justified. With complete remission, treatment 
should end. Gerein et al. [24] reported higher efficacy of interferon in RRP patients with 
HPV 6 as compared with HPV 11. Szeps et al. [25] observed better response in HPV 6 
disease without difference in viral load and hyperproliferation of HPV-infected 
epithelium after treatment. In two recent studies, the beneficial effect of prolonged use of 
interferon-alpha in patients with RRP has been reported reducing the number of required 
laser therapy sessions drastically [26, 27]. However, it appears that interferon does not 
significantly modify the course of RRP when lung involvement occurs [6]. Drug toxicity 
should be monitored although it can be minimized by administering injections at bedtime 
and using preparations produced by recombinant DNA techniques. 
The first patient in the present study had complete remission 13 years after interferon-
alpha cessation. The drug was administered by daily inhalation continuously for a total of 
28 months in an attempt to avoid its systemic side effects that would hinder the 
completion of our treatment strategy. We believe that our patient’s favorable clinical  
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course is due to this continuous and prolonged use of interferon-alpha, according to the 
observations in Leventhal et al.’s study [23]. 
The most recent antiviral agent that has been added in RRP treatment is cidofovir. It 
seems to be effective in improving the outcome of patients with RRP although concerns 
have been raised about its safety profile (e.g. oncogenic potential) [17]. However, a recent 
study showed no cidofovir-induced dysplastic changes in HPV-infected epithelium, it has 
been recommended that the drug should be considered as a treatment option in patients 
with severe refractory disease [28]. 
RRP has the potential for malignant transformation to squamous lung cell carcinoma 
with a dismal prognosis [5, 6]. Malignant degeneration is a rare complication and the 
incidence varies among series. In juvenile RRP, Derkay [29] reported a transformation 
rate of <1%, while in adults a rate of 3–7% has been described [3]. Data from clinical cases 
indicate that HPV 11 is associated with a greater risk of producing lung cancer than HPV 
6, as was the case in our second patient, although rarely HPV 6 can cause bronchial 
carcinomas [30]. Risk factors for malignant transformation in RRP include smoking, 
prior irradiation and HPV type itself. From the history of the second case in our study we 
inferred that the patient was a non-smoker and has had no exposure to radiation prior to 
her admission, thus implying that HPV was the only factor for lung cancer development. 
The precise pathogenesis of malignant transformation in RRP remains elusive. 
However, it has been proposed that HPV exerts its oncogenic power through interfering 
with the cell-cycle. Especially, its oncoproteins E6 and E7 seem to play a key role in 
carcinogenesis, as they promote rapid degradation of tumor suppressor proteins (p53 and 
pRB-retinoblastoma) thus interfering with cell growth control [3]. Not enough data are 
available on the development of mutations and progression to lung cancer in RRP 
patients due to the limited number of patients with lung involvement and lack of HPV 
typing. Nevertheless, molecular studies have confirmed the above-mentioned hypothesis, 
demonstrating that p53 protein mutation or overexpression in the malignant lung tissue 
samples from patients with RRP may result in progressive genetic instability which 
ultimately leads to lung cancer [31–34].  
High-risk HPV are the principal causative agents for cervical malignancies, as has 
clearly been shown in the pioneer studies by zur Hausen [35]. They are found in almost 
100% of all cervical cancer cases. In the early 1980s, Syrjanen [36] first described 
morphological changes in bronchial squamous cell carcinomas quite identical to those 
seen in genital HPV lesions, thus leading to the assumption that HPV could play a role in 
lung carcinogenesis. Since then, there is accumulating evidence implicating an association 
between HPV infection and bronchial cancer given that the well-known risk factors of 
lung cancer (e.g. smoking, occupational exposure, air pollution) cannot explain all lung 
cancer cases [37]. HPV DNA has been found in approximately 20% of all lung cancer 
cases investigated to date, with HPV types 16 and 18 most frequently detected. HPV 
integration itself cannot fully explain an active role of the virus in carcinogenesis without 
formation of papillomas. A recent study showed the presence of E6 and E7 oncogenes and 
their transcripts in HPV-positive lung cancer cases that are prerequisite for cancer 
development, thus reinforcing further the hypothesis that HPV could be a co-factor in 
bronchial carcinogenesis [38]. 
In conclusion, RRP is a relatively rare disease that can cause life-threatening airway 
compromise. Its recurrent nature and numerous palliative treatments have a tremendous  
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influence on patients’ quality of life. Clinicians should be aware of the disease to make an 
early diagnosis that is pivotal for the patients’ clinical outcome. In addition, because of the 
tendency for recurrences and malignant transformation, meticulous follow-up of patients 
including HPV typing is indispensable for early detection and treatment. 
 
 
Fig. 1. Bronchoscopy showing multiple polypoid papillomas in the upper two thirds of the trachea (a). 
Bronchoscopy demonstrating disease remission 13 years after the cessation of interferon-alpha 
treatment; disappearance of tracheal papillomas (b) and a small residual papilloma at the anterior 
commissure (c). 
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Fig. 2. Chest X-ray and computed tomography showing a mass in the right upper lobe associated with 
mediastinal widening (a, b). Fiberoptic bronchoscopy revealing typical papillomas in the larynx (c) and 
trachea (d, arrow) and an exophytic mass obstructing the right upper lobe (d, asterisk). 
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